Isodiol International Inc. Stock Canadian Securities Exchange
Equities
ISOL
CA46500L2003
Pharmaceuticals
Sales 2018 | 19.14M 26.16M | Sales 2019 | 22.25M 30.42M | Capitalization | 49.96M 68.3M |
---|---|---|---|---|---|
Net income 2018 | -36M -49.22M | Net income 2019 | -126M -172M | EV / Sales 2018 | 12.6 x |
Net cash position 2018 | 15.55M 21.26M | Net Debt 2019 | 5.22M 7.14M | EV / Sales 2019 | 2.48 x |
P/E ratio 2018 |
-4.94
x | P/E ratio 2019 |
-0.37
x | Employees | - |
Yield 2018 * |
-
| Yield 2019 |
-
| Free-Float | 100% |
Managers | Title | Age | Since |
---|---|---|---|
Marcos Agramont
CEO | Chief Executive Officer | - | 17-05-23 |
Director/Board Member | - | 18-08-29 | |
Kevin Swadish
PRN | Corporate Officer/Principal | - | 19-02-13 |
Members of the board | Title | Age | Since |
---|---|---|---|
Marcos Agramont
CEO | Chief Executive Officer | - | 17-05-23 |
Director/Board Member | - | 18-08-29 | |
Director/Board Member | - | 18-11-20 |
1st Jan change | Capi. | |
---|---|---|
-15.13% | 4.49B | |
-9.75% | 3.06B | |
+2.14% | 3.04B | |
-6.82% | 2.61B | |
+47.87% | 1.81B | |
+0.09% | 1.66B | |
-7.89% | 1.63B | |
-12.97% | 1.55B | |
+33.40% | 1.41B |